9 Meters Biopharma Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

Stock Information for 9 Meters Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About 9 Meters Biopharma Inc.

9 Meters Biopharma Announces Management Change and Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome
9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2023
9 Meters Biopharma Announces Successful Pre-IND Meeting with FDA Regarding Its GIP Antagonist NM-136 for Obesity
9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2022
9 Meters Biopharma Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
9 Meters Biopharma Announces $5 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
9 Meters Biopharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
9 Meters Biopharma to Present at the 2023 BIO CEO & Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.